Amgen Inc. (NASDAQ:AMGN)
Historical Stock Chart
5 Years : From Jan 2013 to Jan 2018
German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer.
-Financial details of the deal weren't disclosed.
-Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials.
-After the initial trials have been completed, Bayer will be responsible for further development and commercialization of the product candidate.
-In 2009, Bayer had entered into an agreement with Micromet, Inc. to produce another antibody.
-Micromet was acquired by Amgen in early 2012.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500